Varda Space and United Therapeutics Partner on Microgravity Drug Formulation
Varda Space Industries and United Therapeutics have announced a collaboration to explore microgravity-based drug formulation for rare pulmonary diseases, according to a press release.
The companies will conduct pharmaceutical processing aboard Varda's orbital manufacturing and reentry platform during multiple missions to low Earth orbit. The work will focus on how microgravity affects the structure and crystallization of small molecule medicines, with the goal of improving drug stability, bioavailability, and delivery characteristics.
Initial experiments will involve compounds used in treatments for life-threatening pulmonary conditions. Varda's system launches pharmaceutical payloads to orbit, processes materials in microgravity, and returns the finished products to Earth using its W-series reentry capsules.
The collaboration brings together Varda's orbital manufacturing capabilities and United Therapeutics' expertise in drug development to investigate how space-based processing can produce formulations not achievable under terrestrial conditions.
We hope you enjoyed this article.
Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.
Also, consider following us on social media:
More from: Life Sciences
Subscribe to Life AI Weekly
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
Market report
AI’s Time-to-Market Quagmire: Why Enterprises Struggle to Scale AI Innovation
The 2025 AI Governance Benchmark Report by ModelOp provides insights from 100 senior AI and data leaders across various industries, highlighting the challenges enterprises face in scaling AI initiatives. The report emphasizes the importance of AI governance and automation in overcoming fragmented systems and inconsistent practices, showcasing how early adoption correlates with faster deployment and stronger ROI.
Read more